aTyr Pharma, Inc.ATYRNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+37.5%
5Y CAGR+70.9%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+37.5%/yr
vs +9.0%/yr prior
5Y CAGR
+70.9%/yr
Recent deceleration
Acceleration
+28.5pp
Accelerating
Percentile
P95
Near historical high
vs 5Y Ago
14.6x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 40.44% |
| Q3 2025 | -47.37% |
| Q2 2025 | 9.90% |
| Q1 2025 | -17.42% |
| Q4 2024 | 0.20% |
| Q3 2024 | 35.65% |
| Q2 2024 | 8.63% |
| Q1 2024 | -102.31% |
| Q4 2023 | -15.72% |
| Q3 2023 | 20.41% |
| Q2 2023 | -1935.59% |
| Q1 2023 | 94.31% |
| Q4 2022 | 15.57% |
| Q3 2022 | -34.70% |
| Q2 2022 | 9.90% |
| Q1 2022 | -25.14% |
| Q4 2021 | 29.50% |
| Q3 2021 | -49.12% |
| Q2 2021 | -32.01% |
| Q1 2021 | -7.89% |
| Q4 2020 | 2.77% |
| Q3 2020 | 13.24% |
| Q2 2020 | -411.13% |
| Q1 2020 | 141.86% |
| Q4 2019 | -15.59% |
| Q3 2019 | 11.78% |
| Q2 2019 | 19.96% |
| Q1 2019 | -24.47% |
| Q4 2018 | 25.09% |
| Q3 2018 | 29.68% |
| Q2 2018 | 13.14% |
| Q1 2018 | -2.63% |
| Q4 2017 | -15.88% |
| Q3 2017 | 4.12% |
| Q2 2017 | 33.21% |
| Q1 2017 | -18.75% |
| Q4 2016 | 20.37% |
| Q3 2016 | -5.00% |
| Q2 2016 | -11.98% |
| Q1 2016 | -27.01% |